>

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week.

Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook for the future.

In a week of major sector announcements and crowded news airwaves, we are delighted that GEN chose to cover our story, and the full article can be read at the link below.

JPM 2024: NanoSyrinx Wields Original Bacterial Syringe IP for Protein Delivery

Read more news

NanoSyrinx CEO Joe Healey appointed to DSIT’s Engineering Biology Steering Group

In 2023, the UK Government published the “National Vision for Engineering Biology”. The report highlighted the ambitions of the UK to be a world leader in the Engineering Biology (a.k.a. Synthetic Biology) sector, and described how £2BN would be put to work over the next decade, cementing the UK’s position at the front of the […]

Read more

NanoSyrinx at Number 10

Our CEO Joe Healey was invited to Number 10 this week, to discuss the future of Engineering Biology in the UK as part of a networking and investment breakfast. Synthetic biology or “Engineering Biology” has been highlighted as one of the five key technology areas for the UK’s future economy. Understanding how best to incubate, […]

Read more

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more